Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity..
Am J Cardiol. 110(5), 763.
(2012). Renal resistive index for renovascular hypertension: In the quest of the Holy Grail..
J Clin Hypertens (Greenwich). 20(3), 589-591.
(2018). Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018). Residual cardiac risk reduction beyond lipid lowering..
Hellenic J Cardiol. 52(3), 197-203.
(2011). Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome..
World J Gastroenterol. 21(25), 7860-8.
(2015). Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'..
Clin Cardiol. 35(5), 315; author reply 316-7.
(2012). The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification..
Curr Opin Cardiol. 25(4), 394-8.
(2010). The role of endocannabinoid system blockade in the treatment of the metabolic syndrome..
J Clin Pharmacol. 47(5), 642-52.
(2007). The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?.
Expert Opin Ther Targets. 11(2), 191-205.
(2007). The role of statins for the primary and secondary prevention of coronary heart disease in women..
Curr Pharm Des. 15(10), 1054-62.
(2009). The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014). Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis..
Lancet. 376(9756), 1916-22.
(2010). Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients..
Neurol Res. 32(3), 326-31.
(2010). Semaglutide, lipid-lowering drugs, and NAFLD..
Lancet Diabetes Endocrinol. 5(5), 329-330.
(2017). Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention..
Curr Med Res Opin. 31(2), 191-5.
(2015). Should adipokines be considered in the choice of the treatment of obesity-related health problems?.
Curr Drug Targets. 11(1), 122-35.
(2010). Should atenolol still be recommended as first-line therapy for primary hypertension?.
Hellenic J Cardiol. 47(5), 298-307.
(2006). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism..
Expert Opin Pharmacother. 9(4), 509-15.
(2008). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?.
Curr Med Res Opin. 26(4), 839-42.
(2010). Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly..
Atherosclerosis. 238(2), 182-4.
(2015). Statin-fibrate combination for mixed dyslipidaemia: a limited option?.
Curr Med Res Opin. 26(9), 2137-40.
(2010).